The clinical trial aims to evaluate the safety and efficacy of EpCAM CAR-T cell therapy in patients with advanced gastric cancer exhibiting peritoneal metastasis. Given the high mortality rates associated with gastric cancer, particularly in China, successful outcomes could position this therapy as a novel treatment option in a market with significant unmet needs. The trial's focus on a specific patient population that has failed standard therapies may enhance its appeal to oncologists and patients alike. Competitive analysis indicates that while CAR-T therapies are gaining traction in hematological malignancies, their application in solid tumors remains limited, providing a potential first-mover advantage for this asset if successful. Diligence should focus on regulatory pathways and reimbursement strategies for CAR-T therapies in solid tumors.